Hepatocellular carcinoma (HCC) · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | None |
| ID | IND-CHRONIC-HIV-HBV-COINFECTION-PREVENTION-TENOFOVIR-ART |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-HCC |
| Sources | SRC-AASLD-HBV-2024 SRC-AASLD-HCC-2023 SRC-EASL-HBV-2025 SRC-NIH-AIDS-2024 |
Notes
STUB — HIV+HBV coinfection prevention anchor. v0.2-A continuation. Tenofovir-based ART REG-* not yet authored.
Used By
Contraindications
CI-TENOFOVIR-SEVERE-RENAL- CI-TENOFOVIR-SEVERE-RENAL
Indication
IND-CHRONIC-HIV-HBV-COINFECTION-PREVENTION-OBSERVATION- IND-CHRONIC-HIV-HBV-COINFECTION-PREVENTION-OBSERVATION